Search

Displaying results 3971 - 3980 of 8698 in total
  1. Drug

    Streptococcus pneumoniae type 33f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10341
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  2. Drug

    Lotiglipron

    go.drugbank.com/drugs/DB21631
    Investigational

    Lotiglipron is under investigation in clinical trial NCT05579977 (Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People … The usage of the INN stem '-glipron' in the name indicates that Lotiglipron is a glucagon-like peptide 1 receptor (GLPIR) agonist.

  3. Drug

    Kappadione

    go.drugbank.com/drugs/DB09332
    Approved

    Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is

  4. Drug

    Quercus stellata pollen

    go.drugbank.com/drugs/DB10888
    Approved

    Quercus stellata pollen is the pollen of the Quercus stellata plant. Quercus stellata pollen is mainly used in allergenic testing.

    Mixtures: 5-oak Mix, Blackjack/bur/post/red/white Pollen
  5. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  6. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor. … Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual

  8. Target

    Eph receptors

    go.drugbank.com/bio_entities/BE0028186
    TargetHumans

    May play a role in apoptosis … May also regulate angiogenesis. More generally, may play a role in targeted cell migration and adhesion.

    Polypeptides: Ephrin type-A receptor 1, Ephrin type-A receptor 10Synonyms: Tyrosine-protein kinase receptor EPH, Tyrosine-protein kinase receptor ECK
  9. Drug

    Bicifadine

    go.drugbank.com/drugs/DB04889
    Investigational

    Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain. … It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    Furaprevir

    go.drugbank.com/drugs/DB12785
    Investigational

    Furaprevir is under investigation in clinical trial NCT01523990 (A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients).